New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
08:26 EDTOMEROmeros shares oversold, secondary endpoint met, says Maxim
Maxim says that while OMS103HP missed its primary endpoint, the drug met its secondary endpoint of pain. The firm adds that pain is directly related to inflammation and the surgical process itself. Maxim finds Omeros shares oversold and said itís a buyer of the stock.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
09:16 EDTOMEROn The Fly: Pre-market Movers
Subscribe for More Information
07:02 EDTOMEROmeros reports OMS721 inhibits thrombus formation in sera from aHUS patients
Subscribe for More Information
November 13, 2014
08:16 EDTOMEROmeros price target raised to $28 from $20 at Maxim
Maxim raised its price target for Omeros shares to $28 citing better than expected pricing for Omidria. The firm believes global sales of the drug could reach north of $400M by 2017 and keeps a Buy rating on Omeros.
November 10, 2014
16:12 EDTOMEROmeros reports Q3 EPS (54c), consensus (59c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use